BioCardia, Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted NPV of lead cell-therapy program plus net cash: $250M estimated peak annual sales for the CardiAMP/Helix platform in heart failure; 8% probability of regulatory/commercial success; 2x peak-sales NPV multiple; discounted 4 years at an 18% cost of capital; plus ~$3.6M estimated net cash across 15.14M shares.

Reasoning: BioCardia is a pre-revenue cell-therapy company with a thin cash position (~$4.1M) relative to its burn rate, so a probability-weighted rNPV of its lead program blended with net cash better reflects both recent positive regulatory developments in Japan and the US and material near-term financing risk than a conventional FCF-based DCF.